This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Lee, R. T. Search for Related Content PubMed PubMed Citation Articles by Lee, R. T. Related Collections Cardiovascular Pharmacology Gene expression Genomics

(Circulation. 2001;104:1441.)
© 2001 American Heart Association, Inc.

Cardiovascular Drugs

Functional Genomics and Cardiovascular Drug Discovery

Richard T. Lee, MD

From the Cardiovascular Division, Department of Medicine, Brigham and Women’s Hospital, Harvard Medical School, Boston, Mass, and the Division of Bioengineering and Environmental Health, Massachusetts Institute of Technology, Cambridge, Mass.

Correspondence to Richard T. Lee, MD, Partners Research Facility, Room 279, 65 Landsdown St, Cambridge, MA 02139.

Key Words: genes • drugs • molecular biology

	Introduction

 
The history of cardiovascular drug discovery is filled with delightful stories of serendipity. Had William Withering not first advanced his expertise in botany to court Helena Cook, a young woman who enjoyed painting flowers and later became his wife, he may not have been able to identify foxglove as a therapy for heart failure.¹ Similarly, warfarin owes its discovery not to a search for therapeutic anticoagulants, but to studies of a hemorrhagic disease of cattle that devastated the American northern prairie farming community in the 1920s.²

More recently, cardiovascular drugs have arisen less from chance and more from logical scientific approaches. The development of captopril, for example, depended on an understanding of the active site of the angiotensin-converting enzyme and logical chemical modifications of active site antagonists.³ However, advances in genomic technology over the past several years have transformed drug discovery. This article will provide an overview of one new approach to drug discovery that is often called Functional Genomics.

Although the progress of the Human Genome Project and privately-funded genome databases enabled the functional genomics approach, other powerful uses of the genome in drug discovery will be not be discussed in detail here. For example, single-base genomic differences between individuals called single nucleotide polymorphisms are common in candidate genes for cardiovascular diseases⁴ and can be used to identify genes associated with disease susceptibility in populations. Genes associated with disease susceptibility are obvious potential targets for novel therapies, although many of these genes may not be suitable targets for drugs. . . . [Full Text of this Article]

This article has been cited by other articles:

				M. E. Safar and P. Lacolley Disturbance of macro- and microcirculation: relations with pulse pressure and cardiac organ damage Am J Physiol Heart Circ Physiol, July 1, 2007; 293(1): H1 - H7. [Abstract] [Full Text] [PDF]

				S. Lehoux and A. Tedgui All Strain, No Gain: Stretch Keeps Proliferation at Bay via the NF-{kappa}B Response Gene iex-1 Circ. Res., December 12, 2003; 93(12): 1139 - 1141. [Full Text] [PDF]

				V. Dzau Risk assessment in cardiovascular disease: from traditional risk factors to genomics Eur. Heart J. Suppl., August 1, 2003; 5(suppl_F): F48 - F55. [Abstract] [PDF]

				E. O. Weinberg, M. Shimpo, S. Hurwitz, S.-i. Tominaga, J.-L. Rouleau, and R. T. Lee Identification of Serum Soluble ST2 Receptor as a Novel Heart Failure Biomarker Circulation, February 11, 2003; 107(5): 721 - 726. [Abstract] [Full Text] [PDF]